Ceftolozane/tazobactam
Ceftolozane/tazobactam is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
There's more to see -- the rest of this entry is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved